The Food and Drug Administration approved Adamas Pharmaceuticals Inc.'s (Nasdaq: ADMS) GOCOVRI to treat dyskinesia in patient with Parkinson's disease sending the stock price soaring $5.70 to close at $19.93.
FDA approves Adamas Pharmaceuticals' GOCOVRI
August 25, 2017 at 17:21 PM EDT
